Auxilart Selected for FY2025 TOKYO Strategic Innovation Promotion Program (TOKYO戦略的イノベーション促進事業)

TOKYO, March 24, 2026. Auxilart Co., Ltd. (Bunkyo-ku, Tokyo; CEO: Junu Kim), specializing in mathematical modeling and simulation for pharmaceutical manufacturing, has been selected as a supported project under the FY2025 "TOKYO Strategic Innovation Promotion Program" (TOKYO戦略的イノベーション促進事業). The program is administered by the Tokyo Metropolitan Government and the Tokyo Metropolitan Small and Medium Enterprise Support Center.

The program provides grant funding to support technology and product development by Tokyo-based SMEs collaborating with universities, research institutions, and large enterprises to address urban challenges. Fifteen projects were selected for FY2025.

Auxilart's project, titled "Development of an Automated Optimal Condition Search Tool for Cell Culture Processes," falls under the "Healthcare and Medical" development theme. The project focuses on building an automated mathematical model generation system for cell culture processes, along with an optimization tool based on those models.

Through this program, Auxilart aims to contribute to greater efficiency and quality in biopharmaceutical manufacturing process development.

About the TOKYO Strategic Innovation Promotion Program

Program name: TOKYO Strategic Innovation Promotion Program
Administered by: Tokyo Metropolitan Government; Tokyo Metropolitan Small and Medium Enterprise Support Center
Maximum grant: 80 million yen (minimum: 15 million yen)
Grant period: Up to 3 years
Details: https://www.tokyo-kosha.or.jp/support/josei/jigyo/tokyo-innovation.html

The full list of selected projects was announced on March 11, 2026. (https://prtimes.jp/main/html/rd/p/000000026.000175765.html)

About Auxilart

Auxilart is a Tokyo-based technology company focused on accelerating research and development processes through advanced modeling and simulation technologies derived from more than a decade of research at the University of Tokyo. Its mathematical modeling approach enables high-accuracy digital simulations using significantly less experimental data than traditional AI-driven approaches. By replacing a portion of physical experiments with digital simulation, Auxilart contributes to meaningful reductions in both development costs and timelines, helping pharmaceutical companies improve process understanding and accelerate time-to-market.

Since its founding in 2023, Auxilart has delivered modeling and simulation services to a diverse range of clients, primarily leading domestic and international pharmaceutical companies.

Company: https://auxilart.com/

Media Contact

Contact Person: Kay (Keisuke) Okita
LinkedIn: linkedin.com/company/auxilart-co-ltd/
Email: information@auxilart.com